Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity
- PMID: 3343343
- PMCID: PMC442533
- DOI: 10.1172/JCI113391
Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity
Abstract
Two low molecular weight (LMW) apoproteins were isolated from human pulmonary surfactant. SDS polyacrylamide gel analysis showed one protein (SP 18) to have an apparent molecular weight of 18,000 when unreduced and 9,000 D after reduction. The second protein (SP 9) migrated at approximately 9,000 D in the presence or absence of reducing agents. Both proteins contain a high number of hydrophobic amino acids. The NH2-terminal sequence of SP 18 was determined to be: NH2-phe-pro-ile-pro-leu-pro-tyr-. A cDNA clone isolated from a human adult lung cDNA library contained a long open reading frame encoding at an internal position the human SP 18 amino-terminal sequence. Mixtures of phospholipids (PL) and SP 9 and SP 18 were assessed for their capacity to reduce surface tensions on a pulsating bubble surfactometer. The addition of 1% apoprotein resulted in a reduction of surface tension after 15 s from 42.9 dyn/cm for PL alone to 16.7 and 6.3 dyn/cm for preparations containing SP 9 and SP 18, respectively. In vivo assessment of reconstituted surfactant activity was performed in fetal rabbits. Reconstituted surfactant consisting of PL + 0.5% SP 18 instilled intratracheally at delivery resulted in a marked increase in lung compliance, while the incorporation of 0.5% SP 9 yielded a moderate increase. These data show the ability to produce biologically active surfactant by the addition of isolated LMW apoproteins to defined PL.
Similar articles
-
The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants.Pediatr Res. 1991 May;29(5):460-5. doi: 10.1203/00006450-199105010-00010. Pediatr Res. 1991. PMID: 1896249
-
Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo.Pediatr Res. 1995 Jan;37(1):21-5. Pediatr Res. 1995. PMID: 7700729
-
Reconstitution of surfactant activity using purified human apoprotein and phospholipids measured in vitro and in vivo.Am Rev Respir Dis. 1986 Dec;134(6):1258-65. doi: 10.1164/arrd.1986.134.5.1258. Am Rev Respir Dis. 1986. PMID: 3789526
-
[Recent advances in molecular biology with respect to pulmonary surfactant apoproteins].Nihon Rinsho. 1996 Feb;54(2):334-40. Nihon Rinsho. 1996. PMID: 8838078 Review. Japanese.
-
The surfactant system of the lung.Fed Proc. 1974 Nov;33(11):2238-47. Fed Proc. 1974. PMID: 4214720 Review. No abstract available.
Cited by
-
Function and regulation of expression of pulmonary surfactant-associated proteins.Biochem J. 1991 Jan 15;273(Pt 2)(Pt 2):249-64. doi: 10.1042/bj2730249. Biochem J. 1991. PMID: 1991023 Free PMC article. Review. No abstract available.
-
Antigenicity of low molecular weight surfactant species.Am J Pathol. 1989 Apr;134(4):723-32. Am J Pathol. 1989. PMID: 2705504 Free PMC article.
-
Immunogenicity of surfactant. II. Porcine and bovine surfactants.Clin Exp Immunol. 1991 Jan;83(1):41-6. doi: 10.1111/j.1365-2249.1991.tb05585.x. Clin Exp Immunol. 1991. PMID: 1988231 Free PMC article.
-
Surfactant protein B polymorphisms are associated with severe respiratory syncytial virus infection, but not with asthma.BMC Pulm Med. 2007 May 11;7:6. doi: 10.1186/1471-2466-7-6. BMC Pulm Med. 2007. PMID: 17498296 Free PMC article.
-
Regulation of messenger RNAs for the hydrophobic surfactant proteins in human lung.J Clin Invest. 1989 Apr;83(4):1191-7. doi: 10.1172/JCI114000. J Clin Invest. 1989. PMID: 2539393 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases